Otsuka Busulfex's Overall Survival Claim Does Not Survive CDER Advertising Scrutiny
This article was originally published in The Pink Sheet Daily
Statistical analyses based on pivotal trial data and used to promote a drug must prove what they purport to prove, FDA's Office of Prescription Drug Promotion says in an NOV letter to Otsuka over a website for the leukemia drug Busulfex (busulfan).
You may also be interested in...
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
Notice of violation letter to Novartis from FDA’s Office of Prescription Drug Promotion expresses concern about describing a patient with five-year survival data, a claim that was added to the label the following month.
Nycomed gets a "notice of violation" letter for a flashcard that used open-label study data to make claims for its actinic keratoses treatment Solaraze (diclofenac).